Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

  1. Cedillo, S.
  2. González-Domínguez, A.
  3. Ivanova-Markova, Y.
  4. López López, R.
  5. López-Tarruella Cobo, S.
  6. Peña Pedrosa, J.A.
Zeitschrift:
PharmacoEconomics - Open

ISSN: 2509-4254,  2509-4262

Datum der Publikation: 2024

Art: Artikel

DOI: 10.1007/S41669-024-00518-2 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus